Biden's Executive Order, Dems Digital Money Legislation, First Step To

Donald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it.

This means you must act NOW before it's too late.

Dennis A. Ausiello net worth and biography

Dennis Ausiello Biography and Net Worth

Director of Alnylam Pharmaceuticals

Director of the Center for Assessment Technology and Continuous Health; Jackson Distinguished Professor of Clinical Medicine at Harvard Medical School; Physician-in-Chief Emeritus at Massachusetts General Hospital; member of the Institute of Medicine of the National Academy of Sciences and the American Academy of Arts and Sciences; Director of Seres Therapeutics, Spexis AG and Rani Therapeutics and formerly served as Director of Pfizer Inc.

What is Dennis A. Ausiello's net worth?: The estimated net worth of Dennis A. Ausiello is at least $36,989.28 as of August 6th, 2024. Dr. Ausiello owns 136 shares of Alnylam Pharmaceuticals stock worth more than $36,989 as of September 17th. This net worth evaluation does not reflect any other investments that Dr. Ausiello may own. Learn More about Dennis A. Ausiello's net worth.
How do I contact Dennis A. Ausiello?: The corporate mailing address for Dr. Ausiello and other Alnylam Pharmaceuticals executives is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. Alnylam Pharmaceuticals can also be reached via phone at (617) 551-8200 and via email at [email protected]. Learn More on Dennis A. Ausiello's contact information.
Has Dennis A. Ausiello been buying or selling shares of Alnylam Pharmaceuticals?: Within the last three months, Dennis A. Ausiello has sold $5,305,500.00 in shares of Alnylam Pharmaceuticals stock. Most recently, Dennis A. Ausiello sold 20,250 shares of the business's stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $262.00, for a transaction totalling $5,305,500.00. Following the completion of the sale, the director now directly owns 136 shares of the company's stock, valued at $35,632. Learn More on Dennis A. Ausiello's trading history.
Who are Alnylam Pharmaceuticals' active insiders?: Alnylam Pharmaceuticals' insider roster includes Dennis Ausiello (Director), Michael Bonney (Director), Jeffrey Dunn (CEO), Kevin Fitzgerald (EVP), Indrani Franchini (EVP), Pushkal Garg (CMO), Yvonne Greenstreet (COO), Laurie Keating (EVP), John Maraganore (CEO), Steven Paul (Director), Jeffrey Poulton (CFO), David Pyott (Director), Amy Schulman (Director), Phillip Sharp (Director), Tolga Tanguler (EVP), and Akshay Vaishnaw (Insider). Learn More on Alnylam Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Alnylam Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 11 times. They sold a total of 154,848 shares worth more than $34,733,444.48. The most recent insider tranaction occured on August, 20th when CEO Yvonne Greenstreet sold 15,000 shares worth more than $4,200,000.00. Insiders at Alnylam Pharmaceuticals own 1.5% of the company. Learn More about insider trades at Alnylam Pharmaceuticals.
Information on this page was last updated on 8/20/2024.

Dennis A. Ausiello Insider Trading History at Alnylam Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/6/2024	Sell	20,250	$262.00	$5,305,500.00	136
11/2/2017	Sell	20,000	$130.00	$2,600,000.00	20,000
3/19/2015	Sell	5,000	$120.00	$600,000.00
10/22/2014	Sell	5,000	$90.00	$450,000.00

Dennis A. Ausiello Buying and Selling Activity at Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Company Overview

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $271.98

$270.24

$273.88

50 Day Range

MA: $258.84

$233.81

$287.01

2 Week Range

Now: $271.98

$141.98

$287.55

Volume

295,683 shs

Average Volume

889,321 shs

Market Capitalization

$34.40 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.38